Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)
Agafina et al., European Journal of Medical Research, doi:10.1186/s40001-024-02008-x
https://c19early.org/agafina.html